Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ABCB1 polymorphism as a predictive biomarker for amrubicin-induced neutropenia.

Anticancer research - 1 Jul 2014

Takakuwa Osamu, Oguri Tetsuya, Uemura Takehiro, Kunii Eiji, Nakao Makoto, Hijikata Hisatoshi, Kawaguchi Yuko, Ohkubo Hirotsugu, Takemura Masaya, Maeno Ken, Niimi Akio

Abstract excerpt

BACKGROUND: Amrubicin is a promising therapy for lung cancer, but is associated with a high incidence of severe neutropenia. The present study assessed the utility of ABCB1 and NAD(P)H quinone oxidoreductase 1 (NQO1) polymorphism as a predictor of amrubicin-induced neutropenia. MATERIALS AND METHODS: Fifty-four Japanese lung cancer patients who received amrubicin chemotherapy were consecutively recruited and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anthracyclines
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ATP Binding Cassette Transporter, Subfamily B

Share to ATP Binding Cassette Transporter, Subfamily B, Member 1

Share to Dose-Response Relationship, Drug

Share to Lung Neoplasms

Share to NAD(P)H Dehydrogenase (Quinone)

Share to Neutropenia

Source

Identifiers

PMID: 24982363

Genes

ABCB1
NQO1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ABCB1 polymorphism as a predictive biomarker for amrubicin-induced neutropenia.PMID 24982363Read ↗

C609T polymorphism of NAD(P)H quinone oxidoreductase 1 as a predictive biomarker for response to amrubicin.Semantic proximity Read ↗

Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.Semantic proximity Read ↗

ABCG2 genetic variant as risk factor for neutropenia in patients with metastatic or advanced hormone receptor -positive, HER2-negative breast cancer treated with palbociclibSemantic proximity Read ↗

ABCG2 genetic polymorphism as risk factor for neutropenia in patients with metastatic or advanced hormone receptor -positive, HER2-negative breast cancer treated with palbociclibSemantic proximity Read ↗

Genome-wide association study of epirubicin-induced leukopenia in Japanese patients.Semantic proximity Read ↗

Relationship between ABCB1 gene polymorphisms and severe neutropenia in patients with breast cancer treated with doxorubicin/cyclophosphamide chemotherapy.Semantic proximity Read ↗

ABCB1 and ABCC2 genetic polymorphism as risk factors for neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy.Semantic proximity Read ↗

An SNP in CYP39A1 is associated with severe neutropenia induced by docetaxel.Semantic proximity Read ↗

Development of a clinically implementable population pharmacokinetic– pharmacodynamic model and interactive application for therapeutic drug monitoring of amrubicinSemantic proximity Read ↗

Role of pharmacogenetics on adjuvant chemotherapy-induced neutropenia in Chinese breast cancer patients.Semantic proximity Read ↗

Pharmacogenetic association between GSTP1 genetic polymorphism and febrile neutropenia in Japanese patients with early breast cancer.Semantic proximity Read ↗

Over-expression of MDR1 in amrubicinol-resistant lung cancer cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.